Free Newsletter
New approach to vaccine development
The Guardian covers the development of a new generation of virus-vectored vaccines that promise to take on a number of diseases like malaria. Instead of a traditional approach using weakened virus to produce antibodies that fight disease, researchers are adding the genetic code of molecules into the DNA of the virus. That approach is believed to be more effective in supporting a strong immune response. Efficacy trials for the new approach may be mounted in Africa in three to four years, after researchers have had a chance to test a malaria vaccine. The work is being funded by the Bill and Melinda Gates Foundation, which has funneled huge sums into the science.
- read the article on vaccine research from The Guardian
Related Articles:
Gates Foundation restructures, refocuses. Report
Gates adds $287M to HIV vaccine research. Report
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

SHARE
WITH: